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Introduction
Male breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men 
and approximately 1% of all BCs worldwide [1–6]. Less than 0.2% of cancer-related deaths 
in men can be attributed to male BC [7, 8]. Because male BC occurs at a very low incidence, 
BC literature, research, clinical trials, and development of new treatment options primarily 
focus on female BC. Although knowledge about female BC can inform male BC diagnosis 
and treatment, molecular and clinicopathologic features differ between male and female BC. 
Biologic factors, such as sex differences, hormonal regulation, and response to treatment 
(both tolerability and activity), must be considered when defining this disease in men and 
deciding upon treatment options [8]. Currently, no standard of care (SOC) exists for male 
BC, and there is an unmet need for research and therapeutic options for this disease. This 
review summarizes current knowledge of male BC to date with a discussion of future 
treatment options for the disease.
Demographics of Male Breast Cancer
Almost 1% of all BCs occur in men. In 2018, about 2550 men will be diagnosed with BC in 
the US, and male BC will account for 480 deaths. In comparison, it is estimated that there 
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will be approximately 266,120 new cases of female BC and approximately 40,920 deaths 
due to BC in women [9, 10]. According to Surveillance, Epidemiology, and End Results 
Program (SEER) data from 2015, the incidence of invasive BC in men is 1.1:100,000 men, 
whereas it is 126.5:100,000 in women [11]. However, the incidence and prevalence of male 
BC varies by race and ethnicity, and men in certain select populations such as African 
Americans have higher rates of male BC in comparison to their Caucasian, Hispanic, or 
Asian/Pacific Islander counterparts [12]. The median age at initial diagnosis of invasive BC 
is typically older in men than in women (68 versus 62 years) [13]. In both men and women, 
the age-adjusted rate of BC sharply increases by the fifth decade of life. However, the rate 
plateaus in women by the sixth decade of life but continues to increase in men through the 
seventh decade.
Disease Characteristics of Male Breast Cancer
Initial diagnosis of male BC often occurs at a later stage than in female BC, and male BC 
often exhibits more advanced disease features, such as a larger tumor size, lymph node 
involvement, and distant metastases at the time of diagnosis [1, 2, 8, 14–18]. In developed 
countries, nearly two-thirds of invasive female BCs are localized at the time of diagnosis; in 
contrast, in men approximately half of the cases are localized and the other half are regional 
or distant disease [11].
Estimates of in situ carcinoma in men are approximately 10%; the remaining 90% can be 
attributed to infiltrating ductal carcinoma [1, 2, 4, 8, 19]. Infiltrating lobular carcinoma, 
medullary lesions, and tubular or neuroendocrine tumors are very rare in men, as is triple-
negative BC (TNBC) [1, 2, 4, 19, 20]. Male BCs usually express the estrogen receptor (ER), 
progesterone receptor (PR), and androgen receptor (AR); are hormonally responsive; and 
most commonly present as unilateral tumors [5, 17–19, 21–23]. Nipple retraction or the 
palpation of a retroareolar mass is a common physical examination finding and may be the 
first clinical manifestation of male BC [2].
Genetic/Epigenetic Alterations in Male Breast Cancer
A study by Johansson and colleagues revealed that there are 2 main subtypes of male BC: 
the male complex subtype, which is similar to female luminal BC, and the male simplex 
subtype, which does not exist in female BC [24, 25]. These findings have been confirmed by 
results from the International Male Breast Cancer Program (IMBCP) [20]. The IMBCP 
results also revealed additional important alterations using RNA sequencing.
In addition, the research laboratory of one of the authors (J. Parker) has been investigating 
the gene expression patterns of BC using RNA sequencing and other methods [26]. In the 
current analysis, gene expression, somatic mutation, and copy number data for 1098 BC 
samples were acquired from The Cancer Genome Atlas (TCGA) Firehose (The Broad 
Institute Genome Data Analysis Center, https://gdac.broadinstitute.org/). Sex information 
was abstracted from the clinical data for 451 samples, including 5 samples from men. 
Samples without sex information in the available clinical data were assigned as ‘likely’ male 
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(N = 7) or female based on the expression of UTY. Gene expression intrinsic subtypes were 
assigned based on the PAM50 algorithm [27].
At the global level, BC gene expression analyzed with principal component analysis 
provides evidence that male BC is generally similar to female BC, as top components of 
variation do not segregate by sex. Instead, the predominant variation segregates by intrinsic 
subtype, with male BC overlapping with female luminal cases. Supporting this, the male BC 
samples were significantly enriched with luminal cells (Fisher’s Exact P = 0.009). This 
evidence that a majority of male BC samples tested were luminal-type is a distinctly 
different feature compared to female BC, which shows a greater diversity of subtypes. No 
difference in mutation rate was observed between female and male samples. Similar to 
female luminal tumors, individual mutations of GATA3 and PIK3CA are frequent, although 
there are no TP53 mutations in the male BC samples. In a recently published study, the most 
frequently mutated genes in male BC were PIK3CA (20%) and GATA3 (15%) [28], which 
agrees with the findings from the Parker laboratory.
From the perspective of copy number, differences in males and females are not observed 
after accounting for PAM50 intrinsic subtyping. While the number of males in the Parker 
dataset is small (N = 12), these data provide strong support that many if not most male BC 
will be characterized as luminal breast cancer. The characterization of male BC as luminal 
type is in agreement with recent studies in which 29% and 71% of male BCs were classified 
as luminal A–like and B–like, respectively, by immunohistochemistry and in which genetic 
tests of male BC samples showed a pattern of aberrations similar to female BC samples of a 
luminal subgroup [25, 28].
Although male BC seems globally similar to female BC, the evidence from studies 
summarized above indicates that there are common genetic features of female BC that are 
not shared with male BC. Underlying genetic and epigenetic differences between male and 
female BC exist and are summarized in Table 1. For male BC—as with many cancers—
family history plays a large role in an individual’s risk of acquiring the disease. A family 
history of BC increases the risk of male BC [29] (a relative risk of 2.5 [4]), and 20% of men 
with BC have a first-degree relative with BC [6, 29]; the BC risk increases to more than 5-
fold when the number of relatives with BC, especially early onset, increases [30]. Inherited 
germline mutations are a likely etiology for 4% to 40% of male BCs (versus 30% to 86% of 
female BCs) [6, 31, 32]. In particular, mutations in BRCA1 and especially BRCA2 are 
associated with increased BC risk [30]. Estimates of the lifetime risk of developing male BC 
range from 1% to 5% for BRCA1 mutation carriers and 5% to10 % for BRCA2 mutation 
carriers, compared to 0.1% in the general population [33].
Mutations in other DNA-repair genes such as CHEK2 [34] and PALB2 [35] are also 
associated with male BC. In a recently reported study of male BC patients undergoing 
testing with a multigene panel of 8 or more common cancer-related mutations, it was shown 
that more than 13.3% of the men tested positive for one or more of the mutations, and the 
most common mutations in that subset of patients were in BRCA2 (47%), followed by 
CHEK2 (31%), PALB2 (7%), BRCA1 (9%), and ATM (4%) [36]. In addition, genetic 
variation in CYP17, the gene that encodes an enzyme responsible for sex steroid production, 
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has been proposed as a risk factor for breast and prostate cancer. Two case-control studies 
have investigated single nucleotide polymorphisms (SNPs) in CYP17 [37, 38]. One study 
found a polymorphism (a T to C substitution in the promoter region) associated with 
increased risk of male BC but not female BC [37], while the other study found a statistically 
nonsignificant increased risk of the same polymorphism in men with the BRCA2 999del5 
mutation [38]. Another study of CYP17 in a large study of 8138 prostate cancer cases and 
5333 BC cases from the Breast and Prostate Cancer Cohort Consortium found no association 
between common genetic variants in CYP17and prostate cancer or BC [39]. However, the 
majority of BC patients were female, and the results did not address male BC specifically.
Epigenetic alterations have also been implicated in the development and progression of 
cancer. Similar to female BC, promoter hypermethylation is also common in male BC, and 
the methylated genes are common between men and women [40]. The difference is that 
many of the genes investigated have decreased methylation frequency compared to female 
BC, which provides additional differences between male and female BC development and 
progression.
Endocrine Risk Factors Associated with Male Breast Cancer
Klinefelter’s syndrome, a rare genetic condition characterized by the presence of an extra X 
chromosome (XXY genotype) and associated with testicular dysgenesis, gynecomastia, an 
altered balance of androgens and estrogens, and increased gonadotrophins, increases the risk 
of developing male BC up to 50-fold compared to unaffected men [4, 41]. Similar to the 
increased estrogen levels associated with Klinefelter’s syndrome, the use of exogenous 
estrogens, such as estrogen treatment of prostate cancer [42] and hormone therapy for male-
to-female transsexuals [43], increases the risk of male BC. Endogenous causes of 
hyperestrogenization in men, including obesity, cirrhosis, mumps orchitis, undescended 
testes, or testicular injury also have been associated with increased risk of male BC[4, 29]. 
In a comprehensive overview of risk factors for male BC, alcohol consumption, occupation, 
and radiation exposure were implicated as additional risk factors [4]. Interestingly, invasive 
lobular BC is very rare in men due to a lack of terminal breast lobules, except for those who 
are exposed to increased estrogens from endogenous or exogenous sources [44].
Table 1 presents a summary of the major differences between male and female invasive 
breast cancer.
Treatment Options for Male Breast Cancer
While significant efforts have been made to increase female BC awareness, screening, 
diagnostics, and treatment options, research and outreach directed at male BC has been 
limited until recently. Management of male BC has mainly relied on adopting clinical 
practices developed to treat female BC patients [2, 51]. Several studies have indicated that 
the overall survival (OS) estimates for male BC are significantly lower than for female BC 
[15, 21, 52], which emphasizes the need for earlier screening and effective treatments in 
male BC. However, it is important to note that many men with BC tend to have additional 
comorbidities and/or other neoplasms (e.g., prostate cancer, colon cancer, lung cancer) and 
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are more likely to die from other causes compared to women with BC [53]. Because of this, 
some researchers suggest that disease-specific survival (DSS) may be a more accurate 
benchmark for male BC prognosis and survival rates than OS [8, 15] and in particular 
adjusted breast cancer–specific survival (adjusted for age, comorbidities, and stage at 
diagnosis). Studies have found that men had slightly better or equivalent DSS compared to 
women [53, 54], although note that these studies were not controlled for BC subtype. 
Importantly, both the retrospective joint analyses and the prospective registry parts of the 
IMBCP have shown that overall quality of care for male patients with breast cancer is 
worrisomely inferior than that for female patients with BC [19, 20].
Treatment Options for Early-stage Male Breast Cancer
Treatment for early-stage male BC includes 4 main treatment modalities: surgery, radiation 
therapy, chemotherapy, and endocrine therapy [1, 8, 55]. Typically, men with BC are treated 
with modified radical mastectomy, with axillary lymph node dissection or sentinel node 
biopsy [56]. Breast conservation or nipple-sparing or skin-sparing mastectomies may also be 
performed in selected cases; oncoplastic techniques should be used in view of the significant 
psychological and emotional impact of the physical consequences of locoregional therapies 
in male patients. Men are more likely than women to undergo mastectomy and to receive 
adjuvant radiotherapy as they are often diagnosed at a later stage and have nipple or skin 
involvement at diagnosis [29]. While there are limited data on chemotherapy use for male 
BC, clinicians choosing to use chemotherapy typically assess similar clinicopathologic risk 
factors (including tumor size, nodal involvement, hormone receptor status, HER2 status, and 
the underlying biology of the cancer) in male BC patients as they do in female BC patients 
with early-stage disease.
As a majority of male BCs express the ER, the use of endocrine therapy such as tamoxifen is 
routine for the management of male BC. Tamoxifen is the SOC for adjuvant endocrine 
therapy, and aromatase inhibitors should not be used alone in this setting. Aromatase 
inhibitors are not commonly used for the initial treatment of male BC. In gonad-intact men, 
aromatase inhibitors may cause a partial decrease in estrogens but also cause an increase in 
androgens, presumably from a lack of estradiol negative feedback on gonadotropin release 
[57, 58]. This increase in androgens could be problematic given the near-universal AR 
positivity of male BC. In addition, estrogen production in men is 80% by peripheral 
aromatization but 20% by direct testicular production, the latter not being inhibited by an 
aromatase inhibitor alone [insert REF post QC]. For these reasons, if an aromatase inhibitor 
is used, it is recommended that it be co-administered with chemical or surgical castration 
[1]. However, this combination has substantial side effects, which usually are associated 
with low compliance and should be reserved for very select cases. Tamoxifen, a selective 
estrogen receptor modulator therapy, is the current endocrine therapy of choice for male BC, 
given that nearly all male BC tumors are ER+ and that tamoxifen has been shown to improve 
survival rates in ER+ female BC [4, 8]. Although tamoxifen has been shown to be effective 
for male BC, it has drawbacks: frequency of recurrence and side effects that include hot 
flashes, changes in vision, cognitive changes, and a lower sex drive [51, 59–62]. Such 
quality of life issues may discourage male patients from continuing treatment, as 20% to 
25% of men with BC discontinue tamoxifen due to side effects [4, 62]. Retrospective 
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observational analysis has shown that survival of men with ER+, lymph node–negative 
tumors improved with tamoxifen but not with aromatase inhibitors [63]. In male subjects 
with hormone receptor–positive (HR+) disease receiving adjuvant hormonal therapy, a 
significantly (P = 0.007) higher proportion of subjects who received aromatase inhibitors 
died (32%) compared to those who received tamoxifen (18%) [64], providing further support 
of tamoxifen in the adjuvant setting. A prospective, randomized, Phase 2 trial of tamoxifen ± 
gonadotropin-releasing hormone (GnRH) analog versus exemestane + GnRH analog 
investigating endocrine changes in men with HR+ BC found that tamoxifen or exemestane 
given in combination with GnRH analog resulted in reductions in sex steroids (testosterone 
and estradiol) and gonadotropins (follicle stimulating hormone and luteinizing hormone) 
while tamoxifen alone resulted in increases in sex steroid and gonadotropin concentrations 
that were significantly different than either combination [65]. Tumor assessments were not 
reported.
Treatment Options for Metastatic Male Breast Cancer
Since male BC is almost always ER+, the preferred treatment option for first-line therapy of 
metastatic disease is endocrine therapy [66]. Tamoxifen is again the treatment of choice, 
unless relapse occurs while on treatment with this agent. In this circumstance, other 
therapeutic options should be considered such as an aromatase inhibitor (preferably 
associated with a luteinizing hormone-releasing hormone agonist) or fulvestrant. 
Chemotherapy should be reserved for highly symptomatic or visceral crisis situations [66].
The evidence of activity of aromatase inhibitors or fulvestrant in metastatic or locally 
advanced male BC is primarily derived from case reports. In a series of 15 cases of patients 
with metastatic or locally advanced male BC who received aromatase inhibitors, 2 patients 
(13%) had a complete response, 4 patients (27%) had a partial response, 2 patients (13%) 
had stable disease, and 7 patients (47%) had progressive disease; the median progression-
free survival (PFS) was 4.4 months [67]. A limited number of case studies of the selective 
estrogen receptor degrader fulvestrant in men with metastatic BC have shown extended 
partial responses or stable disease [68–70]. Combinations of endocrine and targeted agents, 
such as mTOR and CDK inhibitors, can be used in metastatic male BC patients, as the same 
indications are used for their female counterparts. When chemotherapy is indicated, the 
same agents and regimens recommended for female metastatic BC should be used for male 
metastatic BC.
Clinical Trials in Male Breast Cancer
Due to the rarity of male BC, therapeutic clinical trials targeting solely male BC patients or 
larger BC trials with distinct male cohorts are limited. To date, most male BC patients 
treated in clinical trials have been enrolled in trials that predominantly enroll female patients 
but also allow enrollment of men when eligible. A report in 2010 indicated that there was 
only one therapeutic BC clinical trial that focused solely on men, which closed without 
patient enrollment due to logistical problems and pushback from trial sites [1]. Since then, 
there have been two additional interventional clinical trials opened with a focus on male BC. 
An overview of current or recent clinical trials in male BC is provided in Table 2. Clinical 
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trials are organized by intervention, with a focus on male BC (i.e., solely male BC subjects 
or separate male BC cohort if enrolling female BC subjects), observational male BC, or 
interventional that specifically mention combined enrollment of male and female subjects.
ClinicalTrials.gov was searched for interventional or noninterventional BC clinical trials that 
are recruiting, enrolling by invitation, active, or completed. Of the more than 600 BC clinical 
trials listed, approximately one-third were not exclusionary to male participation. Overall, 
approximately 2% (N = 12) of the trials listed specifically mention the enrollment of men. A 
blog post in May 2016 indicated that the male BC clinical trial landscape is mostly the same 
as in 2013: male participants are eligible for only one-third of BC trials and about 18% of 
Phase 3 trials [71]. Of the 12 trials listed in ClinicalTrials.gov that specifically mention the 
enrollment of men, only 3 are interventional clinical trials (Table 2). Due to the lack of 
interventional clinical trial data, data from observational or retrospective trials, case studies, 
or meta-analyses are leveraged to inform male BC. However, these approaches have 
drawbacks compared to interventional trials, emphasizing the need for randomized, 
controlled, interventional male BC trials. Such an approach requires focused and 
coordinated efforts to increase the feasibility of successful recruitment and completion. 
However, rare disease trials are difficult to operate. For this reason, male BC patients should 
not be excluded from any BC trial unless there is a strong biological reason to do so. This 
will allow for the generation of data on efficacy of new agents in this rare patient population.
Multinational Consortium Approach
Given the paucity of male BC subjects for prospective observational or interventional 
clinical trials, multinational consortium studies are warranted. A major advancement on this 
front is the ongoing International Male Breast Cancer Program, coordinated by the European 
Organisation for Research and Treatment of Cancer (EORTC) and the Translational Breast 
Cancer Research Consortium (TBCRC), under the umbrella of the Breast International 
Group (BIG) and the North American Breast Cancer Group (NABCG), funded by the Breast 
Cancer Research Foundation (BCRF). This program has 3 parts. Part 1 is a retrospective 
joint central analysis of 1822 men, and Part 2 is a 30-month prospective registry that has 
enrolled 557 subjects. Part 3, which involves prospective clinical trials, has yet to be 
initiated.
Part 1 showed low levels of breast-conserving surgery in M0 patients even though a majority 
(56%) of men had T1 tumors [20]. Despite >90% of the tumors being ER+, only 77% of 
patients used adjuvant endocrine therapy. While half of the node-positive patients received 
adjuvant radiotherapy, 36% of N1 and 15% of N2 patients did not. Almost one-third of 
patients received adjuvant therapy. Centralized pathology review of these cases showed that 
the luminal A–like subtype was the most common [72], and that unlike female BC, 
histological grade was not associated with overall survival. An analysis of male BC 
precursor lesions found that ductal carcinoma in situ was the most commonly observed 
precursor lesion in male BC, and its presence seems to be associated with a better outcome, 
particularly in luminal B HER2+ cases [73].
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Initial baseline data from 557 patients enrolled between 2013 and 2017 in the prospective 
registry (Part 2) were recently reported [45]. There continues to be discordance with normal 
treatment patterns with female BC: while 46% of M0 patients enrolled were node-positive, 
only 29% received radiotherapy, and while 98% of men had ER+ disease, only 65% received 
endocrine therapy. Longer follow-up, disease characterization, and comparison to a similar 
female BC population are ongoing.
To date, this program has helped to better understand male BC treatment patterns, tumor 
characteristics, and quality of life, while establishing the foundation for larger multinational 
therapeutic clinical trials, which is the goal for Part 3.
Future Perspectives on Male Breast Cancer and Treatment Options
The research and available literature on male BC has expanded in the past few decades, and 
the progress of the IMBCP is an important step; however, knowledge is limited as clinical/
translational research on male BC is still in its infancy. Although common female BC 
treatment practices are applied to the management of male BC, the medical community 
recognizes male BC as a distinct disease characterized by varied molecular and 
clinicopathologic features. Modified radical mastectomy as well as radiotherapy and 
adjuvant tamoxifen are still used in the treatment of male BC; however, the role of adjuvant 
systemic therapies in male BC is less understood [8]. Several endocrine, cytotoxic, and 
targeted therapies studied in in the metastatic male BC setting have shown variable 
responses [1, 4, 8, 14, 22, 74]. As indicated in Table 2, some ongoing BC trials evaluating a 
variety of new therapies include male patient recruitment and will provide important 
information. However, research specifically dedicated to male BC, especially research 
related to the best endocrine-based approaches, is warranted.
As discussed above, DNA damage repair (DDR) genes, specifically BRCA2, are frequently 
mutated or overexpressed in male BC. Given this, therapies targeting the poly-ADP-ribose 
polymerase (PARP) family of proteins could provide therapeutic benefit to male BC patients 
and warrant investigation. Specifically, PARP1 has been the focus of the most oncology 
research, as it is involved in 80% to 90% of DNA repair via the base excision repair (BER) 
pathway [75, 76]. Inhibition of PARP causes accumulation of single-strand DNA breaks, 
which are converted to double-strand breaks during DNA replication [77, 78]. Since 
mutation of BRCA2 results in the inability to resolve double-strand breaks (DSBs) via the 
high-fidelity homologous recombination pathway, DSBs are resolved by the more error-
prone nonhomologous end joining pathway, which accelerates genomic instability to 
facilitate tumor cell death via the principle of synthetic lethality [78]. Knowledge about the 
efficacy of PARP1 in male BC is very limited. However, PARP inhibitors have shown 
activity in other BRCA-mutated male tumors, including prostate cancer. Indeed, results from 
the TOPARP-A trial (Trial of PARP Inhibition in Prostate Cancer) showed 88% of the 
patients who had a DDR pathway mutation responded to the PARP inhibitor, olaparib [79]. 
Thus, investigation of PARP inhibitors in DDR-deficient male BC should be considered.
The role of AR in BC is an area of active research [80], and AR has become a promising 
potential target for the treatment of male BC [51]. Recently, AR has been found to have 
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prognostic significance in ER+ male BC [81]. A review by Imamura and Sadar provide a list 
of current therapies targeting AR that are used to treat castration-resistant prostate cancer 
(CRPC) [82], and some of these therapies are also potential candidates for treating male BC. 
To date, data exists from female BC trials of 3 compounds that have activity in CRPC: 
bicalutamide (a competitive inhibitor of AR binding), enzalutamide (a competitive inhibitor 
of AR binding and signaling), and seviteronel (a CYP17 lyase and AR inhibitor). A trial of 
the third compound, sevitoronel, includes separate male BC activity data.
In a Phase 2 trial of bicalutamide in women with metastatic AR+ TNBC, 5 of 26 patients 
had stable disease for at least 6 months. The resulting 24-week clinical benefit rate (CBR, 
the proportion of patients who showed a complete response, partial response, or stable 
disease) was 19% [83], and the median PFS was 12 weeks (95% confidence interval [CI], 
11–22 weeks). Bicalutamide was well tolerated in this patient population and could provide 
a potential new therapeutic option for male BC, but it has not been evaluated to date.
Similarly, the activity of enzalutamide has been suggested in AR+ TNBC and AR+/ER+ BC 
[84, 85]. For patients with AR+ metastatic TNBC, a Phase 2 study of single-agent 
enzalutamide 160 mg met its primary endpoint with a CBR at 16 weeks of 35% and a 
median PFS of 14 weeks. Eight percent of patients had either a partial or complete response 
confirmed by RECIST criteria [86]. A randomized, placebo-controlled, Phase 2 study was 
conducted to evaluate exemestane with or without enzalutamide in 247 patients with HR+/
HER2- male BC. The study met its primary endpoint, improving median PFS with the 
addition of enzalutamide to exemestane in the prespecified subset of patients who tested 
positive for the predictive biomarker developed in parallel [87]. Comparable improvement in 
PFS was not observed in women who had 1 prior endocrine therapy for advanced BC. 
Enzalutamide was well tolerated in both of these studies [87, 88]. Despite initial activity in 
female BC patients, development of enzalutamide in BC and the planned Phase 3 trial in 
TNBC were suspended [89].
Seviteronel, a nonsteroidal CYP17A1 and AR inhibitor, is in Phase 2 development for 
advanced prostate and breast cancers (Table 2), and unlike bicalutamide or enzalutamide, it 
has specifically been investigated in male BC [82]. Seviteronel blocks the synthesis of sex 
steroids (androgens and downstream estrogens) via CYP17 lyase inhibition and 
competitively inhibits the AR [90]. Fast-track designation was granted for seviteronel for 
CRPC in 2016 [91] and for male and female BC in 2017 [92]. Full results for the initial 
Phase 2 trials of seviteronel in BC and CRPC are not yet available; however, preliminary 
data from the Phase 2 trial in BC (NCT02580448) indicate that clinical benefit in Stage 1 of 
the trial was encouraging and sufficient to support accrual to Stage 2 for both women with 
ER+ BC and women with TNBC [93] as well as men with BC. Early Phase 2 results for the 
male BC cohort recently reported that 2 of the first 7 subjects enrolled met the initial activity 
endpoint of CBR at 16 weeks, with 1 of 2 patients remaining on seviteronel at 24 weeks. 
The most common adverse event was fatigue [94]. Phase 2 enrollment is ongoing. While 
these results are preliminary, this is the largest prospective therapeutic male BC clinical trial 
to date and the results highlight the potential for AR-targeted agents for the treatment of 
male BC.
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While male BC is a rare and often neglected disease, there is a growing understanding of the 
biological differences between male and female BC. Such differences indicate that male BC 
should be seen as a separate disease, distinct from female BC. The effective treatment of 
patients with male BC remains a clinically challenging scenario with many unanswered 
questions. Research in this area is focused on evaluating the underlying biology of this 
subtype of tumors with the goal of developing improved therapeutic strategies for the 
management of this underrepresented population. An understanding of germline mutations 
with increased prevalence in male BC, such as BRCA2, may help with the identification of 
novel treatment options such as PARP inhibitors. Also, given the near universal expression 
of the AR in male BC tumors and relatively benign safety profile, AR-targeted agents may 
prove beneficial as a treatment option, either as monotherapy or in combination with other 
agents. Early activity of seviteronel in male BC highlights the targeting of the sex-steroid 
biosynthesis pathway and AR activation as a promising therapeutic approach for male BC. 
Future research in this area will require coordinated multicenter international collaboration 
to conduct larger, successful therapeutic clinical trials in male BC that lead to the 
development and approval of novel targeted agents for the management of this rare disease.
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Table 1
Comparison of Male and Female Invasive Breast Cancer
Characteristic Male Female Comments
Patient Demographics
Incidence 2550 266,120 2018 US estimates [9, 10]
Annual deaths 480 40,920 2018 US estimates [9, 10]
Median age at diagnosis, years 68 [13] 62 [13]
Age-adjusted incidence rates (per 100,000 individuals)
 All years 1.2 124.8 SEER 2011–2015 [11]
 20–49 y 0.2 7.14
 50–64 y 1.8 270.1
 65–74 y 5.2 426.0
 75+ y 7.7 414.3
Disease Characteristics
BC distribution at diagnosis
 Localized 63.1% 45.4% SEER 2006–2015 [11]
 Regional 29.1% 43.6%
 Distant 5.7% 8.1%
 Unstaged 2.1% 2.9%
Histological type
 Ductal 89% 73% Prospective analysis of 449 male BC patients 
samples [44]; Retrospective analysis of 
190,458 female BC cases [45] Lobular 1% 8%
 Other 9% 19%
Receptor status
 ER+ 99% 77% Retrospective analysis of 1483 male BC 
patients samples [20]; Retrospective analysis 
2171 female BC patient samples [46] PR + 82% 64%
 AR+ 97% 77%
 HER2 + 9% 11%
 TNBC 0.3% 11%
Genetic/Epigenetic Alterations
CYP17 gene aberration Common Rare [36, 37]
Klinefelter’s syndrome (XXY) BC rates increase 20- to 50-
fold compared to XY males 
[4]
None [4]
Hypermethylation of BRCA1, 
BRCA2, CD44, ESR1, STK11, 
RARB, and ATM promoter regions
Rare [39] Common [39]
BRCA1 germline mutation Rare (∼1%) [29] Rare ∼5–10%) [47]
BRCA2 germline mutation Common (∼12%) (60% – 
76% in male BC patients 
with multiple family 
members with BC) [29]; 
pathogenic variants increase 
risk 13.9-fold [48]
Rare (∼5%) [47]
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Characteristic Male Female Comments
CHEK2 mutations Pathogenic variants increase 
risk 3.7-fold [48]




PALB2 mutations Pathogenic variants increase 
risk 6.6-fold [48]
AR androgen receptor, ATM ataxia telangiectasia mutated, BC breast cancer, BRCA breast cancer gene, CD44 CD44 molecule (Indian blood 
group), CHEK2 checkpoint kinase 2, ER estrogen receptor, ESR1 estrogen receptor 1, HER2 human epidermal growth factor receptor 2, PALB2 
partner and localizer of BRCA2, PR progesterone receptor, RARB retinoic acid receptor beta, SEER Surveillance, Epidemiology, and End Results 
Program, STK11 serine/threonine kinase 11, TNBC triple-negative breast cancer, US United States
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Table 2
Clinical Trials for Male Breast Cancer or Clinical Trials in Breast Cancer Enrolling Men
NCT Number / 
Study Type
Status Population Total N 
(Male BC 
N)
Arms Primary Endpoint Sponsor





Men only, hormone 
receptor +,

















Men only, recurrent or 
metastatic or recurrent 
BC, ER+ or PR+
0 Anastrozole + 
goserelin 
acetate









women; Phase 1: 
women only, TNBC 
or ER+ / Phase 2: 
TNBC, AR+ or ER+
175 (21) Seviteronel CBR16 (female 











Men only with or 
without male BC, > 






exposure and the 
development of 
breast cancer in 
men.






Men only, invasive 
breast carcinoma




Part 2: prospective 
observational recently 




N/A Survival, PFS, time 
to locoregional or 
distant relapse, 









































Men and women, 
recurrent or metastatic 
BC, ER+, PR+, 
HER2−











Men (1) and 
postmenopausal 
women (99), ER+ 
and/or PR+
100 Dasatinib + 
fulvestrant, 
fulvestrant







Men (1) and women 











Objective response Hoffmann-La 
Roche
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NCT Number / 
Study Type
Status Population Total N 
(Male BC 
N)








Men and women, 
metastatic BC, 
HER2−
114 PEGPH20 + 
eribulin (several 
doses) / eribulin










80 Drug U3-1402 Safety and 
tolerability (AEs/

















MTD and RP2D Memorial Sloan 
Kettering Cancer 
Center
AE adverse event, AR androgen receptor, Aug August, BC breast cancer, CBR16 clinical benefit rate at 16 weeks, CBR24 clinical benefit rate at 24 
weeks, DLT dose-limiting toxicity, ER estrogen receptor, GnRH gonadotropin-releasing hormone, HER2 human epidermal growth factor receptor 
2, HER3 human epidermal growth factor 3, Jan January, MTD maximum tolerated dose, N/A not applicable, ORR objective response rate, OS 
overall survival, PD progressive disease, PEGPH20 PEGylated recombinant human hyaluronidase, PFS progression-free survival, PR progesterone 
receptor, RP2D recommended Phase 2 dose, SAE serious adverse event, TEAE treatment-emergent adverse event, TNBC triple-negative breast 
cancer
Note: Bolded NCT numbers indicate clinical trials with only male participants.
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